US Biologic, Inc. Launches Innovative Technology for Poultry Health
US Biologic, Inc. has made a significant advancement in poultry health with the introduction of an innovative method to fight diseases without relying on traditional antibiotics. This groundbreaking development aims to tackle the challenges presented by coccidiosis and antimicrobial resistance, which currently lead to major economic losses within the poultry industry.
The Challenge of Coccidiosis and Antimicrobial Resistance
Coccidiosis represents a major health issue for poultry, contributing to estimated annual losses of around $3.5 billion in the industry. Along with the growing threat of antimicrobial resistance, this reality highlights the pressing need for fresh solutions. The use of antibiotics in livestock has resulted in the rise of resistant bacteria strains, which are often referred to as "superbugs." These pose serious risks not just to animals, but also to human health.
Introducing cNK-2
In partnership with the Agricultural Research Service (ARS) of the U.S. Department of Agriculture, US Biologic, Inc. has undertaken extensive research and testing on an innovative, orally delivered technology known as cNK-2. This biologic solution serves as a non-antibiotic alternative that has demonstrated promising outcomes in trials targeting coccidiosis.
Encouraging Results from Trials
Dr. Hyun S. Lillehoj, a Research Molecular Biologist with USDA-ARS, highlighted the importance of these findings. Through rigorous testing, cNK-2 has been shown to be as effective as traditional antibiotics, but without the danger of fostering resistance. This represents a significant step forward, especially since past efforts to discover viable non-antibiotic alternatives have often fallen short.
Advantages of the New Oral Drug
The introduction of cNK-2 offers several benefits for poultry producers. According to Dr. Jolieke G. van Oosterwijk, the Chief Scientific Officer at US Biologic, this new solution not only helps maintain bird weight but also reduces the risk of disease transmission. Furthermore, cNK-2 operates independently of antibiotics, making it a safer choice for both poultry and consumers.
Plans for Future Implementation
Looking ahead, Dr. van Oosterwijk noted that they plan to conduct larger-scale trials to fine-tune the dosage and navigate the regulatory landscape. This upcoming stage may involve partnerships with leading companies in the animal health sector, potentially amplifying the impact of cNK-2 on poultry production systems.
Addressing Antimicrobial Resistance
Antimicrobial resistance is escalating into a global health crisis. Dr. Paul Plummer, the Executive Director of the National Institute of Antimicrobial Resistance Research and Education, affirmed the significance of research initiatives like these. The work by US Biologic marks a critical advancement in antibiotic stewardship, helping to ensure that antibiotics remain effective for future generations.
Investing in Agricultural Research
This groundbreaking initiative is supported by various organizations, including the USDA’s National Institute of Food and Agriculture through the Small Business Innovation Research Program. Such funding is essential for ongoing innovation and research in agricultural practices that can ultimately yield substantial economic gains.
About US Biologic, Inc.
US Biologic, Inc. is committed to developing effective solutions for disease prevention in livestock. With a focus on oral, thermostable, and multi-species vaccines and biologics, the company seeks to combat some of the most serious public health challenges posed by animal diseases. Their comprehensive approach emphasizes global collaboration and practical solutions that benefit producers, animals, and consumers alike.
Frequently Asked Questions
What is the main goal of cNK-2?
The primary aim of cNK-2 is to provide an effective, non-antibiotic alternative to help combat coccidiosis in poultry while tackling concerns about antimicrobial resistance.
How does cNK-2 stack up against traditional antibiotics?
cNK-2 has been shown to be as effective as traditional antibiotics in fighting coccidiosis, but it does not contribute to the development of antibiotic-resistant bacteria.
What’s next for cNK-2?
The next steps include larger trials, refining dosages, and working through the regulatory process while potentially forming partnerships within the industry.
Why is antimicrobial resistance a pressing issue?
Antimicrobial resistance poses serious health threats as it creates superbugs—bacteria that are difficult to treat—thus putting human and animal health at risk.
What is the USDA's role in this research?
The USDA collaborates with US Biologic through its Agricultural Research Service to provide support and conduct research focused on innovative agricultural practices.
